Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

The Multi-Heart Plate: a human engineered mini-heart platform for functional cardiac disease modelling and drug testing

Obiettivo

Cardiovascular diseases remain a leading cause of mortality worldwide, yet drug development is hampered by the lack of predictive human models that capture cardiac function. In particular, diastolic dysfunction and heart failure with preserved ejection fraction represent major unmet medical needs, partly because current preclinical models inadequately reproduce human cardiac physiology. This HEARTPUMP project aims to explore the innovation potential of the Multi-Heart Plate (MHP), a novel human stem cell-based platform developed in the ERC Advanced Grant HEART2BEAT. The MHP consists of miniature engineered cardiac chambers capable of pumping fluid and generating quantitative functional readouts such as cardiac output, ejection fraction and relaxation kinetics. This enables direct assessment of cardiac performance and drug responses in a physiologically relevant human model. HEARTPUMP will combine technical validation and commercial feasibility activities. Technically, we will demonstrate the reproducibility and robustness of the platform, develop and validate a diastolic dysfunction disease model, and establish a drug screening portfolio to benchmark predictive performance against existing models. Workflow optimization, including automated data analysis and assay standardization will further improve scalability and usability for drug discovery. In parallel, we will engage with pharmaceutical and biotechnology companies and contract research organizations to assess industry requirements and obtain early feedback. Intellectual property strategy and market analysis will be conducted with technology transfer experts to evaluate commercial opportunities and guide the development of a business plan. Together, these activities will demonstrate the technical and commercial feasibility of the MHP platform and establish the basis for its translation into cardiovascular drug discovery, potentially through creation of a spin-out company or alternative commercialization pathways.

Campo scientifico (EuroSciVoc)

Questo progetto non è ancora stato classificato con EuroSciVoc.
Suggerisci i campi scientifici che ritieni più rilevanti e aiutaci a migliorare il nostro servizio di classificazione.

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) ERC-2026-POC

Vedi tutti i progetti finanziati nell’ambito del bando

Istituzione ospitante

UNIVERSITEIT TWENTE
Contributo netto dell'UE
€ 150 000,00
Indirizzo
DRIENERLOLAAN 5
7522 NB Enschede
Paesi Bassi
Regione
Oost-Nederland Overijssel Twente
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
Nessun dato

Beneficiari (1)